Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer

Wahi, Abhishek; Manchanda, Namish; Jain, Priti; Jadhav, Hemant R

doi:10.1016/j.bioorg.2023.106833

Cited by 2 publications

(4 citation statements)

References 207 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The bromodomain and extra‐terminal domain (BET) family serves as an epigenetic reader of post‐translational modifications. Bromodomains (BRDs) specifically recognize acetylated lysine (KAc) in both histone and nonhistone proteins via the BRD [1–4] . The human genome encodes 61 BRDs in 46 different BRD‐containing proteins, and The BET family comprises four members in humans (bromodomain containing 2 protein (BRD2), bromodomain containing 3 protein (BRD3) and bromodomain containing 4 protein (BRD4), and testis‐specific bromodomain (BRDT) [5] …”

Section: Introductionmentioning

confidence: 99%

“…Since BET proteins have been found to play a critical role in the formation of various cancer types, inhibiting the BRD‐histone interaction is seen as a new and attractive pathway in cancer treatment. The structural identification of the hydrophobic pocket in which the KAc‐BRD complex is formed, allows the development of small inhibitor molecules in this context [1,3–7] …”

Section: Introductionmentioning

confidence: 99%

“…Bromodomains (BRDs) specifically recognize acetylated lysine (KAc) in both histone and nonhistone proteins via the BRD. [1][2][3][4] The human genome encodes 61 BRDs in 46 different BRD-containing proteins, and The BET family comprises four members in humans (bromodomain containing 2 protein (BRD2), bromodomain containing 3 protein (BRD3) and bromodomain containing 4 protein (BRD4), and testis-specific bromodomain (BRDT). [5] BET proteins play critical role in most hematological and solid tumors by acting as coactivators in the expression of proliferative genes.…”

Section: Introductionmentioning

confidence: 99%

“…The structural identification of the hydrophobic pocket in which the KAc-BRD complex is formed, allows the development of small inhibitor molecules in this context. [1,[3][4][5][6][7] Flavones are compounds with a benzo-γ-pyrone structure that form the color and odor of vegetables and fruits in nature. There are approximately 9000 different flavonoid derivatives isolated from plants, and people have been consuming plants rich in flavonoids for the treatment of various diseases for years.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

New Flavone Derivatives Targeting BET Proteins in Cancer: Synthesis, Structure Analysis and Investigation of Bromodomain Inhibitory Activities**

Gultekin,

Ozkan,

Bakar‐Ates

et al. 2023

ChemistrySelect

View full text Add to dashboard Cite

Bromodomains (BRDs) are key transcriptional regulators that control expression of genes. Dysfunction of BRDs has been associated with the development of aggressive tumors. BRDs have emerged as attractive candidates for the development of inhibitors targeting gene transcription. Flavones can act as a potent anticancer agent. In this paper, a series of ten new flavonylquinazoline sulfonamide compounds (FQ1‐FQ10) was synthesized and their cytotoxicity was investigated in human A549 lung carcinoma, MCF‐7 breast carcinoma ve K562 myeloid leukemia cell lines. The most cytotoxic compounds FQ1 and FQ6 were tested for their bromodomain containing 2 protein (BRD2), bromodomain containing 3 protein (BRD3) and bromodomain containing 4 protein (BRD4) inhibitor activities. The results showed that new FQ1 and FQ6 flavone compounds exhibited BRD2, BRD3 inhibitor activity. We suggest that flavonylquinazoline sulfonamide compounds have the potential to inhibit bromodomain activity, thus may be pharmacologically of interest for further investigations.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

New Flavone Derivatives Targeting BET Proteins in Cancer: Synthesis, Structure Analysis and Investigation of Bromodomain Inhibitory Activities**

Gultekin,

Ozkan,

Bakar‐Ates

et al. 2023

ChemistrySelect

View full text Add to dashboard Cite

show abstract

Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets

Liu,

Dai,

Jin

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

Metastasis remains the principal cause of cancer-related lethality despite advancements in cancer treatment. Dysfunctional epigenetic alterations are crucial in the metastatic cascade. Among these, super-enhancers (SEs), emerging as new epigenetic regulators, consist of large clusters of regulatory elements that drive the high-level expression of genes essential for the oncogenic process, upon which cancer cells develop a profound dependency. These SE-driven oncogenes play an important role in regulating various facets of metastasis, including the promotion of tumor proliferation in primary and distal metastatic organs, facilitating cellular migration and invasion into the vasculature, triggering epithelial-mesenchymal transition, enhancing cancer stem cell-like properties, circumventing immune detection, and adapting to the heterogeneity of metastatic niches. This heavy reliance on SE-mediated transcription delineates a vulnerable target for therapeutic intervention in cancer cells. In this article, we review current insights into the characteristics, identification methodologies, formation, and activation mechanisms of SEs. We also elaborate the oncogenic roles and regulatory functions of SEs in the context of cancer metastasis. Ultimately, we discuss the potential of SEs as novel therapeutic targets and their implications in clinical oncology, offering insights into future directions for innovative cancer treatment strategies.

show abstract

Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer

Cited by 2 publications

References 207 publications

New Flavone Derivatives Targeting BET Proteins in Cancer: Synthesis, Structure Analysis and Investigation of Bromodomain Inhibitory Activities**

New Flavone Derivatives Targeting BET Proteins in Cancer: Synthesis, Structure Analysis and Investigation of Bromodomain Inhibitory Activities**

Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets

Contact Info

Product

Resources

About